fashion -WSS

fashion

author：entertainment 2025-09-28 04:13:03 - browse：629

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： How the messy conversation about Dolly changed bioethics

leisure time

WSS

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

A daunting task: navigating dual Medicare, Medicaid eligibility

Poor hospice wound care hurts patients and families

Poor hospice wound care hurts patients and families

David Liu startup to focus on CRISPR delivery

Hospitals look to new technology to keep health care workers safe

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Medicare details structure of new drug price negotiation program

PBMs drew scrutiny in House hearing — and so did pharma

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why the drug industry's warnings on the IRA's impact fall short

After affirmative action ruling, medical educators look to 'holistic review'

David Liu startup to focus on CRISPR delivery

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Akili changes sales model for its ADHD video game treatment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Astellas still sees hope in its gene therapy after four deaths

focus

Covid’s new normal has set in amid another rise in cases

Poor hospice wound care hurts patients and families

Neurocrine congenital adrenal hyperplasia trial succeeds

Transgender sports debate: Physicians say bans are health issue

Patients, doctors press FTC to beef up hospital merger scrutiny

Anthos stroke drug appears safer than common blood thinner

hotspot

hotspot

leisure time

hotspot